| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP and CFO | SVP and CFO | Chief Financial Officer
2 companies
Thomas Charles Reilly last filed a Form 4 in July 2024, as EVP and CFO at AMRN. The filings on record cover 2 companies. Thomas Charles Reilly's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 94,305 shares of AMRN.
Thomas Charles Reilly has 16 Form 4 filings on record from October 2020 to July 2024, across 2 companies: EVP and CFO at Amarin Corp Plc\uk (AMRN), 2022–2024; Chief Financial Officer at Tvardi Therapeutics (TVRD), 2020–2022.
The 29 reported transactions were 11 option or other derivative awards, 6 option exercises, 6 tax withholdings and 4 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $51K.
The largest open-market sale was 1,982 shares of TVRD at an average $14.20 on August 30, 2021, about $28K. Twelve months later TVRD was down 30%.
Shares as reported in the last Form 4 for each company; the most recent is from July 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.